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resumo 
 
 
Objectivos: Os receptores tirosina cinase MET, ErbB-2 e EGFR foram 
identificados como tendo um papel importante no desenvolvimento e
progressão de cancro. O objectivo deste estudo foi determinar a expressão e 
procurar interacções dos receptores MET, ErbB-2 e EGFR em linhas celulares 
de carcinomas de tiróide e mama, e em tumores mamários.  
Métodos: Neste estudo a expressão e interacções dos receptores MET, ErbB-2 
e EGFR foi determinada em duas linhas celulares de carcinoma da tiróide
(TPC-1 e 8505C) e em duas linhas celulares de carcinomas da mama (MDA-
MB-231 e SkBr3). A expressão de MET foi também estudada, por 
Imunohistoquímica, numa serie de 219 carcinomas invasivos da mama, em 
microarrays, com um acompanhamento dos pacientes de 13 anos. 
Resultados: Observámos que MET, ErbB-2 e EGFR são expressos em todas 
as linhas de tiróide e mama, e observámos também interacções entre MET e
ErbB-2. Na série de tumores mamários a expressão de MET foi 
significativamente relacionada com factores de prognóstico bem estabelecidos
como ErbB-2, receptor de estrogénio, grau histológico e subtipos moleculares, 
sendo também significativamente associada com a diminuição da sobrevida 
das pacientes. Por análise multivariada MET demonstrou ter um valor 
prognóstico independente.  
Conclusões: O nosso estudo sugere que a comunicação entre MET e ErbB-2
pode ter um importante impacto clínico-patológico e que merece uma futura 
investigação, nomeadamente ao nível do desenvolvimento de novas
terapêuticas.  
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abstract 
 
Aims: Receptor tyrosine kinases (RTKs) MET, ErbB-2 and EGFR have been 
identified to play an important role in cancer development and progression. Our
aim was to determine MET, ErbB-2 and EGFR expression and search for their 
interactions in thyroid and breast carcinoma-derived cell lines and human 
breast tumours.  
Methods: We have studied the RTKs expression and interactions in two thyroid 
carcinoma-derived cell lines (TPC-1 and 8505C) and in two breast carcinoma-
derived cell lines (MDA-MB-231 and SkBr3). We have also studied, by 
Immunohistochemistry, MET expression on a series of 219 invasive breast 
carcinomas with 13-year disease follow, using tissue-microarray.  
Results: We observed that MET, ErbB2 and EGFR were expressed in both
thyroid and breast cell lines, and we found physical interactions between MET
and ErbB2. In the series of breast tumours, MET expression was significative
correlated with established prognostic factors such ErbB-2, oestrogen receptor 
(ER), grade and subtype, and was also significatively associated with poor 
clinical outcome of the patients. By multivariate analysis MET showed to have
an independent prognostic value.  
Conclusions: Our study suggests that the cross-communication between MET, 
and ErbB-2 may have clinicopathological impact and deserves further analysis 
namely in the design of novel combined therapeutic approaches.  
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Figure 1: Human Receptor Tyrosine Kinases Family. The prototypic receptor for each 
family is indicated above the receptor, and the known members are listed below. 
Abbreviations: AB, acidic box; CadhD, cadherin-like domain; CRD, cysteine-rich domain; 
DiscD, discoidin-like domain; EGFD, epidermal growth factor-like domain; FNIII, 
fibronectin type III-like domain; IgD, immunoglobulin-like domain; KrinD, kringle-like 
domain; LRD, leucine-rich domain. RTK members in bold and italic type are implicated in 
human malignancies. (Adapted from Blume-Jensen & Hunter, 2001). 
 
Figure 2: ErbB receptor activation — a structural view. The three-dimensional (3D) 
coordinates and a schematic representation of the extracellular and intracellular domains of 
ErbB receptors. The plasma membrane is represented by a purple arc. In the diagrams of 
the ectodomain, domain I is colored purple, domain II green, domain III red and domain IV 
dark blue. The ligand (EGF) is colored yellow. The dimerization loop, a part of domain II, 
is in orange. Left: before ligand binding, domains II and IV are connected through an 
intramolecular bond involving the dimerization loop, thereby preventing the formation of a 
high-affinity ligand binding site, which is composed of domains I and III. Middle: ligand 
binding induces major conformational changes and unmasks the dimerization. Right: 
receptor dimerization mediated by the exposed dimerization loops. In the diagrams of the 
intracellular domain, the N-lobe of the kinase domain is colored grey and the C-lobe cyan. 
Helix a-C is dark grey (adapted from Bublil & Yarden, 2007). 
 
Figure 3: The ErbB signalling network. a. Ligands and the ten dimeric receptor 
combinations. Numbers in each ligand block indicate the respective high-affinity ErbB 
receptors. b. Signalling to the adaptor/enzyme layer, shown only for two receptor dimers, 
the weakly mitogenic EGFR homodimer and the relatively potent ErbB2/ErbB3 
heterodimer. c. How the signals are translated to specific types of output. (Adapted from 
Yarden & Sliwkowski, 2001). 
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Introduction    
 
 
Receptor tyrosine kinases  
 
Receptor tyrosine kinases (RTKs) are cell-surface allosteric enzymes, a subclass of 
transmembrane-spanning receptors with an extracellular ligand binding domain, a 
transmembrane domain and an intracellular tyrosine kinase domain.  
The tyrosine kinase activity is promoted by extracellular ligand binding. This binding 
induces a noncovalent oligomerization, mostly dimerization of monomeric receptors that 
will lead to the autophosphorilation of tyrosines in the carboxil terminal segment. Once 
activated, the receptor recruits other molecules that function as docking sites for 
downstream signal transduction molecules (Blume-Jensen & Hunter, 2001). 
The RTKs are the high affinity cell surface receptors of many ligands such as polypeptide 
growth factors, cytokines and hormones that activate intracellular pathways which regulate 
cell division activity, differentiation and morphogenesis. 
More than half of the known RTKs have been repeatedly found either mutated or 
overexpressed in human malignancies. In fact, more than 70% of the known oncogenes 
and proto-oncogenes involved in cancer code for tyrosine kinases. 
Oncogenic receptor tyrosine kinases induce inappropriate activation of downstream 
signalling components that leads to enhanced cell proliferation and increased cell survival, 
through the mitogenic and survival pathways respectively (Krauss, G., 2003). 
There are 58 transmembrane RTKs identified thus far, classified in 20 different families 
(Robinson et al., 2000) (Figure 1).  
This work is focus on the Epidermal Growth Factor (EGF) and Hepatocyte Growth Factor 
(HGF) receptors families. 
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Figure 1. Human Receptor Tyrosine Kinases Family. The prototypic receptor for each family is indicated 
above the receptor, and the known members are listed below. Abbreviations: AB, acidic box; CadhD, 
cadherin-like domain; CRD, cysteine-rich domain; DiscD, discoidin-like domain; EGFD, epidermal growth 
factor-like domain; FNIII, fibronectin type III-like domain; IgD, immunoglobulin-like domain; KrinD, 
kringle-like domain; LRD, leucine-rich domain. RTK members in bold and italic type are implicated in 
human malignancies. (Adapted from Blume-Jensen & Hunter, 2001). 
 
 
Epidermal Growth Factor Receptor family /ErbB Family  
 
The subclass I of the RTKs superfamily consists of the ErbB or EGF Receptors and 
comprises 4 structurally related members: EGFR/ErbB1/HER1, ErbB2/HER2/neu, 
ErbB3/HER3 and ErbB4/HER4. All ErbB members have in common an extracellular 
ligand binding cystein-rich domain, a single membrane-spanning region, and a cytoplasmic 
protein tyrosine kinase containing domain (Hynes & Lane, 2005).  
Under normal physiological conditions, the activation of the ErbB receptors is controlled 
by a spatial and temporal expression of their ligands, members of the EGF-related peptide 
growth factor family. Each ErbB receptor is an inactive monomer that dimerizes, in 
different homo- and heterodimers, in response to ligand binding.  
The ErbB family of ligands can be divided in three groups, comprising 11 members: the 
first includes EGF, transforming growth factor-α (TGF-α) and amphiregulin, all three 
binding specifically to EGFR; the second group includes betacellulin, heparin-binding 
EGF (HB-EGF) and epiregulin, which bind either to EGFR and ErbB4; the third group is 
composed of neuregulins (NRGs) and it is subdivided into two subgroups based on their 
capacity to bind ErbB3 and ErbB4 (NRG1 and NRG2) or only to ErbB4 (NRG3 and 
NRG4) (Hynes & Lane, 2005).  
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Two out of the four ErbB proteins, namely EGFR and ErbB4, are autonomous, when 
bound by a ligand they undergo dimerization and generate intracellular signals. The other 
two receptors are non-autonomous. ErbB2 do not bind to soluble ligands, however acts as a 
preferred partner in heterodimeric complexes with other ligand bound ErbBs. ErbB3 
cannot generate signals because the kinase function on this receptor is impaired. 
Nevertheless, in the context of a heterodimer, primarily with ErbB2, ErbB3 can enhance 
potent intracellular signals (Bublil & Yarden, 2007). 
The extracellular region of each ErbB receptor consists of four domains I-IV (Figure 2).  It 
was shown that the domains I and III are essential for peptide binding, that the direct 
receptor-receptor interaction is induced by domain II (dimerization arm), and that ligands 
are not involved in this receptor-receptor interaction (Hynes & Lane, 2005).  
When EGFR or ErbB3 are free of ligand they assume a tethered structure and the domain 
II is blocked by intramolecular interactions between domains II-IV. The structure of ErbB2 
extracellular region is radically different due to have a fixed conformation that resembles 
the ligand-activated state: the domain II-IV interaction is absent and the dimerization loop 
in domain II is exposed, explaining why this receptor is the preferred partner for the other 
activated ErbBs.  
 
Figure 2. ErbB receptor activation — a structural view. The three-dimensional (3D) coordinates and a 
schematic representation of the extracellular and intracellular domains of ErbB receptors. The plasma 
membrane is represented by a purple arc. In the diagrams of the ectodomain, domain I is colored purple, 
domain II green, domain III red and domain IV dark blue. The ligand (EGF) is colored yellow. The 
dimerization loop, a part of domain II, is in orange. Left: before ligand binding, domains II and IV are 
connected through an intramolecular bond involving the dimerization loop, thereby preventing the formation 
of a high-affinity ligand binding site, which is composed of domains I and III. Middle: ligand binding 
induces major conformational changes and unmasks the dimerization. Right: receptor dimerization mediated 
by the exposed dimerization loops. In the diagrams of the intracellular domain, the N-lobe of the kinase 
domain is colored grey and the C-lobe cyan. Helix a-C is dark grey (adapted from Bublil & Yarden, 2007). 
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Two of the main pathways activated by the receptors are the Mitogen-Activated Protein 
Kinase (MAPK) and the Phosphatidylinositol 3-kinase (PI3K) pathway (Figure 3).  
The MAPK pathway is involved in all ErbB-receptor activations, and the PI3K pathway is 
triggered downstream of most active dimers. For example, whereas PI3K couples directly 
with ErbB3 and ErbB4, it does so indirectly with EGFR and ErbB2, via an intermediary 
adaptor protein known as Cbl, as a result the potency and kinetics of this pathway 
activation differ from the MAPK pathway (Yarden & Sliwkowski, 2001). 
The ErbB signalling system comprises a highly complex and interactive “multilayered” 
network. Signals are initiated at the cell surface where ligand-receptor interactions take 
place, and the resulting receptor dimerization and activation relays and amplifies the signal 
through an intricate cytoplasmic system of enzymes, proteins, and small-molecule 
secondary messengers. This process of signal transduction culminates in the nucleus where 
gene control and protein transcription are modified, producing effects on key cellular 
regulatory processes, such as differentiation, adhesion, growth, migration, and apoptosis 
(Mass, R. 2003). 
 
Figure 3. The ErbB signalling network. a. Ligands and the ten dimeric receptor combinations. Numbers in 
each ligand block indicate the respective high-affinity ErbB receptors. b. Signalling to the adaptor/enzyme 
layer, shown only for two receptor dimers, the weakly mitogenic EGFR homodimer and the relatively potent 
ErbB2/ErbB3 heterodimer. c. How the signals are translated to specific types of output. (Adapted from 
Yarden & Sliwkowski, 2001). 
 
Aberration of ErbB family receptors function is implicated in major pathologies, such as 
cancer or neurodegenerative diseases. It is well documented that excessive ErbB 
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signalling, arising from receptor overexpression, mutations or autocrine stimulation, is a 
characteristic of a wide variety of solid tumours like neoplasms of the brain, breast, lung, 
ovary, pancreas, prostate and thyroid. As an example, high EGFR expression was found in 
the majority of carcinomas, and amplification of ErbB2 gene can be found in 20-30% of 
metastatic breast lesions. As a consequence, ErbB receptors are attractive candidates for 
targeted therapy. In fact, several anti-ErbB monoclonal antibodies and small molecule 
tyrosine kinase inhibitors (TKIs) are currently under investigation, or have been already 
licensed, like Gefitinib for EGFR and Trastuzumab for ErbB2 (Bublil & Yarden, 2007). 
 
 
Epidermal Growth Factor Receptor 
 
Epidermal Growth Factor Receptor (EGFR) is the first member of the ErbB receptor 
family. This receptor is a 170 kDa transmembrane cell surface glycoprotein encoded by the 
ErbB proto-oncogene located on the chromosome 7 at p12.3-12.1. 
The ErbB receptors are implicated in the development of many types of cancer, being 
EGFR the first tyrosine-kinase receptor to be linked directly to human tumours (Schiff et 
al., 2004).  
Activation of the proto-oncogene encoding EGFR contributes to cellular transformation 
and provides to tumour cells substantial growth and survival advantages. High levels of 
this receptor and its ligands have been recognized as a common component of several 
cancer types, including bladder, breast, colon, head and neck, lung carcinomas and 
gliomas. 
Aberrant EGFR activation, which is mediated through gene amplification, mutations and 
autocrine stimulation, appears to be an important factor in tumourigenesis as well as an 
essential driving force for the aggressive growth behaviour of cancer cells and poor 
prognosis. Its activation contributes to several other tumourigenic mechanisms including 
tumour survival, invasion, resistance to apoptosis, angiogenesis and metastatic spread 
(Ensinger et al., 2004). 
The high frequency of abnormalities in EGFR signalling in human carcinomas and gliomas 
together with laboratory and clinical studies showing that inhibition of this receptor can 
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impair tumour growth indicate this receptor as an attractive target for the development of 
cancer therapeutics (Dancey & Freidlin, 2003).  
Several small molecule inhibitors of EGFR are currently in use to treat non-small cell lung 
carcinoma (NSCLC) patients, like Gefitinib (Iressa) and Erlotinib (Tarceva), or in clinical 
trials. These inhibitors disrupt EGFR kinase activity by binding the adenosine triphosphate 
(ATP) pocket within the catalytic domain, inhibiting downstream signalling, thus 
preventing tumour-cell proliferation and angiogenesis, inducing apoptosis. Furthermore, 
additive or synergistic cytotoxic effects are observed on tumour cells when used in 
combination with standard cancer therapies (Guo et al., 2008).  The response rates to any 
EGFR inhibitor are strongly associated with the presence of somatic mutations within the 
tyrosine kinase domain of the receptor. In this way only a subfraction of patients with 
tumours dependent on EGFR for growth and survival respond clinically to EGFR 
inhibitors (Mitsiades et al., 2007). 
 
 
ErbB2 
 
ErbB2 is the second member of ErbB family. This receptor is a 185 kDa transmembrane 
cell surface glycoprotein encoded by the ErbB-2 proto-oncogene located on the 
chromosome 17 at q21.2 (Kremser et al.; 2003). 
ErbB2 is the preferred partner of the ligand bound EGFR, ErbB3 and ErbB4 for the 
formation of catalytically active heterodimers. From these complexes, the ErbB2/ErbB3 
heterodimers are more stable and consequently have a more potent signalling (Pinkas-
Kramarski et al.; 1998). 
It is known that normal human cells constitutively express a small amount of ErbB2 
protein in the plasma membrane. The overexpression of this receptor in pathological 
conditions is usually due to gene amplification, being originally detected in breast tumours 
(Freudenberg et al.; 2005). Lately, was shown that ErbB-2 overexpression is found in a 
wide range of human carcinomas originated in different organs such bladder, colon, 
pancreas, lung, ovary and stomach (Ménard et al.; 2003). Overexpression leads to an 
increase of tumourigenicity, tumour invasiveness, increased metastatic potential, and 
altered sensitivity to hormonal and chemotherapeutic agents (Freudenberg et al.; 2005). 
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Mutations in the kinase domain of ErbB-2 proto-oncogene were recently identified. 
According to Stephens et al., 2004, three unambiguous somatic mutations were identified 
in primary NSCLC: two in-frame insertions and a missense substitution. In this study two 
other likely somatic mutations, corresponding to two different in-frame insertions, were 
also detected in two additional tumours, all located in the kinase domain, however no 
normal tissue was available to compare. It was also shown that the ErbB-2 
immunohistochemical staining revealed no differences between tumours with or without 
mutations, indicating that the overexpression probably does not accompany the mutation. 
In addition three further somatic mutations were found, one in a glioblastoma, one in a 
gastric tumour and other in an ovarian tumour, all of them in the kinase domain. 
In the NSCLC the ErbB-2 mutations were located in the exons 19 and 20, point mutations 
and in-frame insertions respectively, also in the kinase domain (Willmore-Payne et al.; 
2006). In an hepatocarcinoma a single novel missense somatic mutation was found, 
occurring in the activation domain, which alters a basic hydrophilic residue to an acidic 
hydrophilic residue, this mutation is expected to affect the activation domain function 
(Bekaii-Saab et al.; 2006). 
 
 
Hepatocyte Growth Factor receptor family 
 
The HGFR family is structurally distinct from others RTK families. MET, RON and SEA 
are the known proto-oncogenes of this family coding for receptors.  
Mesenchymal Epithelial Transition factor receptor (MET) is the only high affinity receptor 
known for Hepatocyte Growth Factor (HGF), a multifunctional cytokine stimulating cell 
proliferation, motility and extracellular matrix invasion (Wasenius et al., 2005). 
MET is encoded by MET proto-oncogene, located in the chromosome 7 at q31-34, is a 
single pass cell membrane glycoprotein dimeric molecule composed of a 50KDa α chain 
disulfide-linked to a 145KDa β chain in a αβ complex of 190KDa. The α chain is exposed 
at the cell surface and the β chain spans the plasma membrane, both α and β subunits are 
necessary for the biological activity. The intracellular domain of this receptor includes a 
divergent juxtamembrane region followed by a conserved tyrosine kinase catalytic domain 
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and a C-terminal sequence, which is responsible for receptor coupling to intracellular 
transducers (Longati et al., 2001).  
MET and its ligand HGF are expressed in a variety of tissues, and their expression is 
normally confined to cells of epithelial and mesenchymal origin, respectively. The 
transduction of signalling of HGF by MET and subsequent biologic effects has been shown 
to be important in epithelial-mesenchymal interaction and regulation of cell migration, 
motility, cell proliferation and survival, angiogenesis, morphogenic differentiation, and 
organization of three-dimensional (3D) tubular structures (e.g. renal tubular cells and gland 
formation) during development and tissue repair.  
At molecular level, binding of HGF to the MET extracellular ligand-binding domain 
results in receptor multimerization and trans-phosphorylation of multiple tyrosine residues 
at the intracellular region. Tyrosine phosphorylation at MET juxtamembrane, catalytic, and 
cytoplasmic tail domains regulate the internalization, catalytic activity, and docking of 
regulatory substrates, respectively. Activation of MET leads to the binding and 
phosphorylation of adaptor proteins such as Gab-1, Grb2, Shc, and c-Cbl and subsequent 
activation of signal transducers such as PI3K, PLC-γ, STATs, ERK 1 and 2, and FAK 
(Christensen et al., 2004) (Figure 4). 
 
Figure 4. MET pathway. HGF binds to the extracellular domain of MET, which induces tyrosine kinase 
activity, transducing intracellular signalling through a cascade of mediators (ovals). This results in up-
regulation of several transcription factors producing altered cellular physiology (pale blue boxes) with 
salutary effects on disease endpoints (dark blue boxes).Adapted from www.angion.com/science.asp 
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The first alteration of the MET gene was identified in a chemically treated DNA-
transfected human osteosarcoma cell line. In subsequent studies, amplifications of MET 
have been demonstrated in colorectal cancer, point mutations have been specifically 
associated with papillary carcinoma of the kidney, and overexpression has been 
demonstrated in a variety of epithelial tumours, including papillary carcinoma of the 
thyroid (Ruco et al., 2001).  
Deregulated activation of MET can induce tumour-invasive growth into the surrounding 
tissues and penetration into the vasculature. Some studies propose that MET mutations are 
common in cancer metastasis, suggesting a role in metastasis formation (DiRenzo et al., 
2000). 
The interactions between MET and EGFR proteins, and MET and ErbB-2 proteins in 
cancer are beginning to be studied. In 2000 Bergstrom et al., have shown that the presence 
of an autocrine activation of the EGFR in several thyroid carcinoma cell lines resulted in 
an increased MET expression and activity, indicating a cross-communication between the 
two growth factor receptors signalling pathways. In NSCLC this relationship was also 
documented by Guo et al., 2007 and Agarwal et al., 2009. A recent study from Shattuck et 
al., 2008 reports that MET is frequently expressed in ErbB2 overexpressing breast cancer 
cells. Importantly, Shattuck et al. observed in a in vitro model that MET contributes to 
Trastuzumab (monoclonal antibody against ErbB2) resistance, whereas MET activation 
protects cells against Trastuzumab action by abrogating p27 induction. Remarkably, ErbB2 
overexpression breast cancer cells rapidly up-regulate MET expression after Trastuzumab 
treatment, promoting their own resistance and suggesting that a subset of ErbB2 
overexpression patients may benefit from combined inhibition of ErbB2 and MET. 
 
 
Thyroid cancer and RTKs 
 
Although tumours of thyroid account for only 1% of the overall human cancer burden, it is 
the most prevalent type of endocrine malignancy. This type of cancer occurs primarily in 
young and middle aged women’s, with approximately 122,000 new cases per year 
worldwide.  
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Thyroid carcinomas can be caused by environmental, genetic and hormonal factors and 
comprise a heterogeneous group of neoplasms with distinctive clinical and pathological 
characteristics (DeLellis, R. 2006). Because of the thyroid dependence on environmental 
iodine, it is particularly vulnerable to the radioactive iodine effects and to thyroid 
stimulating hormone (TSH) stimulation resulting from iodine deficiency (DeLellis et al., 
2004). 
According to the World Health Organization (WHO) classification of tumours, the main 
histological types of thyroid carcinomas are characterized on the basis of histological and 
clinical parameters.  
Follicular cell derived carcinomas are divided into well-differentiated, poorly differentiated 
(PDTC) and undifferentiated or anaplastic types (ATC) (Figure 5). The well-differentiated 
carcinomas are subdivided in Papillary (PTC), which accounts for about 80% of all thyroid 
carcinomas, and Follicular (FTC) carcinomas. The vast majority of follicular cell derived 
tumours are indolent neoplasms. Nevertheless anaplastic thyroid carcinomas are among the 
most aggressive of all human malignancies with a high mortality and a mean survival of 6 
months after the diagnosis.  
 
Figure 5. Schematic representation of the histological features of follicular cell derived tumours. 
Abbreviations: NT, normal thyroid; PTC, papillary thyroid carcinoma; FVPTC, follicular variant of papillary 
thyroid carcinoma; FTC, follicular thyroid carcinoma; ATC, anaplastic thyroid carcinoma. 
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The expression and the role of EGFR in thyroid carcinomas is still controversial and yet to 
be clarified. In some preclinical studies EGF has been shown to stimulate follicular cell 
proliferation and to enhance the migration and invasiveness of papillary thyroid cancer 
cells. The literature generally supports that EGFR have a low expression in the normal 
thyroid tissue but is overexpressed in anaplastic and papillary thyroid carcinomas (Schiff et 
al., 2004). Other studies, such as Mitsiades et al., 2007, consider that EGFR is usually not 
overexpressed or overactivated in thyroid carcinomas compared with adjacent non-
malignant thyroid tissue.  
Also the role played by ErbB2 in thyroid carcinomas is still controversial. Several studies 
were performed examining the expression of this protein in thyroid carcinomas, leading to 
conflicting results (Freudenberg et al.; 2005). In papillary carcinoma (and also in normal 
thyroid), ErbB-2 expression occurs mainly in the cytoplasm, possibly indicating an 
internalization of the ligand-receptor complex and its degradation. No mutations or 
amplification were referred (Soares et al., 1994; Utrilla et al., 1999; Gumurdulu et al., 
2003; Kremser et al., 2003; Freudenberg et al., 2005). 
It is consistently reported that the MET protein is distinctly overexpressed in PTC. By 
immunohistochemistry the MET overexpression is well documented, being the expression 
levels of the protein low in normal thyroid tissue, thyroid adenomas, and in nonneoplastic 
thyroid diseases such Grave’s and Hashimoto’s diseases (Wasenius et al., 2005). Protein 
overexpression was not associated with amplification or rearrangements of the MET gene 
and the MET protein produced by tumour cells did not show major structural alterations 
(Ruco et al., 2001). Some authors suggest the possibility of a link between MET 
overexpression and RET rearrangements, which are detected in 20-50% of cases of PTC 
(Ivan et al., 1997). 
 
 
Breast cancer and RTKs 
 
Breast cancer is a heterogeneous disease composed of a growing number of recognized 
biological subtypes. It encompasses a wide variety of pathological entities and a range of 
clinical behaviours. Its clinical signs, symptoms and prognosis depend largely on whether 
Receptor Tyrosine Kinases interactions in human cancers                               
12 
the disease is confined or has metastasized to adjacent or distant parts of the body (Baselga 
& Norton, 2002).  
Breast cancer has the highest incidence of all cancers in women, and according to the data 
from Portuguese League against Cancer (www.ligacontracancro.pt), breast cancer is the 
most frequently diagnosed cancer in Portuguese women, one in each ten Portuguese 
women will develop this disease during life, being diagnosed about 4.500 new cases per 
year. 
Breast cancer classification can be approached from two main standpoints. The first is 
based on the histological appearance in combination grading system, in which grading 
includes proliferation rate, degree of differentiation and nuclear pleomorphism. The second 
approach is to classify breast cancers on the basis of a marker that can predict a probable 
response to a particular treatment, such as expression of hormone receptors (oestrogen and 
progesterone) and ErbB-2. At least 15% of breast cancers lack the expression of oestrogen 
receptors (ERs), progesterone receptors (PRs), and ErbB-2, being referred to as triple-
negative cancers (TNCs). TNCs generally have a poor prognosis and are a heterogeneous 
group of cancers (Gusterson, 2009).  
Expression profiling analyses using microarrays have demonstrated that breast cancers can 
be classified according to their expression patterns into three groups. Luminal, when they 
have the characteristics of luminal cells, Basal, when express genes usually expressed in 
normal basal/myoepithelial cells and ErbB2 overexpression (Kapp et al., 2006, Milanezi et 
al., 2008, Weigelt et al., 2008). 
Luminal carcinomas are currently subdivided into A and B. The luminal A have usually a 
low histological grade, an excellent prognosis and show high levels of expression of ER-
activated genes. Luminal B carcinomas co-express ER and ErbB2 and show a higher 
histological grade, higher proliferation rates and a poorer prognosis than luminal A 
tumours. Basal-like carcinomas are ER and ErbB2 negative, and characteristically express 
Cytokeratin 5, 14 and 17, P-chaderin and EGFR. This group of carcinomas is reported to 
have a more aggressive clinical behaviour, and less significant response to conventional 
chemotherapy than luminal breast carcinomas. ErbB2 overexpressing tumours are 
associated with lack or reduced ER expression, overexpression of ErbB-2, and have very 
aggressive clinical behaviour (Milanezi et al., 2008). 
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The role of EGFR in breast carcinogenesis is still poorly established. To date, there are no 
widely agreed criteria for analysis of EGFR status as a predictive or prognostic marker for 
this disease (Chan et al., 2006). EGFR overexpression in 16-36% of breast cancers has 
been reported by Bhargava et al., 2005. No EGFR-activating mutations were found. 
The association of ErbB2 expression with cancer is best studied in breast carcinomas 
where the ErbB-2 gene is amplified and overexpressed in about 20-30%, conferring a more 
aggressive behaviour, a significantly lower survival rate and a shorter time to relapse 
(Yarden & Sliwkowski, 2001; Menendez et al., 2006; Palmieri et al., 2007). 
According to the few works available MET overexpression in breast cancer is associated 
with tumour progression and correlates with poor survival and decrease relapse-free. MET 
receptor overexpression is an independent predictor of poor prognosis in breast cancer 
(Bonine-Summers et al., 2007; Garcia et al., 2007; Lindermann et al., 2007; Shattuck et 
al., 2008).  
 
 
Aims 
 
The study of tyrosine kinase receptors has been a major issue in cancer research. However, 
most of the studies relay in the individual expression of RTKs. Assessment of RTKs gene 
expression and protein interactions not only improves the ability to diagnose and classify 
neoplasms, but also helps to design new therapeutic strategies.  
Our general aim was to go ahead RTKs expression in order to evaluate putative receptor 
interactions in both thyroid and breast tumour models.  
 
Specific aims 
 
Evaluate the expression of ErbB-2, EGFR and MET in cell lines from two tumour models, 
specifically thyroid and breast cancer. 
Characterize the interaction levels between ErbB-2, EGFR and MET, both in thyroid and 
breast cancers cell lines. 
Explore in a human cancer model (human breast cancer) the biological and prognostic 
implications of MET expression and the relation between the expressions of the receptors.  
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Materials and Methods  
 
 
Cell culture 
 
Five human thyroid-derived cell lines were maintained in culture. Two cell lines derived 
from papillary thyroid carcinoma (PTC) – TPC-1 and K1, one derived from follicular 
thyroid carcinoma (FTC) – XTC-1 and two derived from undifferentiated thyroid 
carcinoma (UTC) – C643 and 8505C. 
Three human breast carcinoma-derived cell lines were maintained in culture. The ErbB-2 
overexpressing (ErbB-2 OE) subtype SkBr3 derived-cell line, the basal subtype MDA-
MB-231 derived-cell line and the luminal A MCF-7 derived-cell line. 
TPC1, C643 and 8505C cell lines were maintained in RPMI-1640 (GIBCO) with 10% fetal 
bovine serum (FBS) (GIBCO) and 1% Penicillin-Streptomycin (Pen-Strep) (GIBCO).   
The K1 cell line was maintained in 2:1:1 Dulbecco’s modified Eagle’s medium (DMEM) 
(GIBCO), Ham’s F-12 medium (GIBCO), MCDB104 supplemented with 10%FBS 
(GIBCO), 1% Pen-Strep (GIBCO), 1% L-Glutamine (GIBCO), 0.5% Sodium Pyruvate 
(NaPyr) (SIGMA) and 1.25% Sodium bicarbonate (NaHCO3) (SIGMA).                                                      
The XTC-1 cell line was maintained in 1:1 DMEM:Ham’s F12 medium (GIBCO) 
supplemented with  10%FBS (GIBCO), 1% Pen-Strep (GIBCO), 0.1% Insulin 10mg/ml 
(SIGMA), 0.5% TSH 2.00U/ml (SIGMA) and 0.5% Fungizone 250ng/ml (GIBCO). 
All the three breast carcinoma-derived cell lines were maintained in 1X DMEM (GIBCO) 
with 10% FBS (GIBCO) and 1% Pen-Strep (GIBCO). 
All the cell lines have adherent cell growth. The cells were incubated at 37ºC in a humid 
atmosphere with 5% carbon dioxide. 
 
 
Tissue Samples 
 
A series of breast carcinomas collected by the Institute of Pathology from Araçatuba, 
Brazil, was provided by Prof. Fernando Schmitt from IPATIMUP. This series was 
composed by 219 invasive carcinomas in 23 Tissue Microarrays (TMAs), with a well 
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established follow-up, age and lymph node metastasis information. A classification by 
subtypes had been previously completed, being 138 Luminal, 21 ErbB-2 OE and 60 triple 
negative tumours, and a classification by grade was also performed, being 105 tumours 
grade I, 84 grade II and 30 grade III. All the most important markers of breast carcinomas 
had already been tested, such as ER, ErbB-2, PR, P-chaderin, P53, P63 and EGFR. 
 
 
Protein extraction and quantification 
 
Culture cells were lysated using Catenin lysis buffer and centrifuged at 14000rpm, 4ºC for 
15minutes. The supernatant was kept at -20ºC. 
Sample protein quantification was made by a colorimetric assay, based on the Bradford 
MM method, using the DC Protein Assay Kit (Bio-Rad). Bovine serum albumin (BSA) 
was used as standard, at several known concentrations (0%, 0.5%, 0.75%, 1%, 1.5% and 
3%). The absorbance values (at 655nm) were determined using a microplate reader (Model 
680, Bio-Rad). A standard curve was calculated and the samples’ protein concentrations 
inferred. 
 
 
Co-Immunoprecipitation (Co-IP) 
 
One of the most used and rigorous demonstration of protein–protein interaction is the Co-
Immunoprecipitation (Co-IP) of suspected complexes from cell extracts. Co-IP confirms 
interactions from a whole cell extract where proteins in their native conformation are 
present in a complex mixture of cellular components that may be required for successful 
interactions. 
 
For Co-IP, 150µl of Protein G Sepharose 4 Fast Flow beads (GE Healthcare) were washed 
with Buffer C and centrifuged (14000rpm, 4ºC) for three times, after which, 150µl of 1% 
BSA in Phosphate Buffer Saline (PBS) were added to the pellets. 
  Materials and Methods 
  17 
Total protein lysate (750µg) was incubated with 1µg/µl MET clone 3D4 (Zymed) and as 
control the same amount of protein was incubated with 1µg/µl Normal Mouse IgG 
(Upstate Millipore). Mixtures were incubated at 4ºC for 16 hours. 
To each mixture, 50µl of the beads were added and a 45 minutes incubation at 4ºC was 
performed, thus enabling the immobilization of the protein-protein complexes on the 
protein G sepharose beads. Unbound proteins were then removed by a series of washes in 
Buffer C. The protein complexes kept in the pellet were then eluted from the beads, 
dissociated and denaturated by incubating with a solution of Laemmli1.5%, bromophenol 
blue 0.25% and β-mercaptoethanol at 95ºC for 5minutes. SDS-PAGE of samples was then 
performed followed by Western blotting with specific antibodies for the bait (MET) and 
prey partners. 
 
 
Small interfering RNA (siRNA) for MET downregulation 
 
Short small interfering RNA (siRNA) is a class of short double-stranded RNA molecules 
(20-25 nucleotides), and interfering RNA (RNAi) is the methodology used to downregulate 
the expression of specific genes. In this specific case, MET was downregulated and its 
effects in other known proteins in the cells were assessed. 
 
TPC-1, MDA-MB-231 and SkBr3 cells were plated in a 6-well tissue culture plate (TPP, 
Techno Plastic Products), 1.0 X105cells/well and 1.2 X105cells/well respectively, and 
grown in standard culture conditions until 60% confluence was reached. The respective 
culture medium was then changed to regular medium without antibiotics two hours before 
transfection. Cells were transfected with MET-specific siRNA oligonucleotides (Qiagen) 
and as control with Allstars Negative Control siRNA oligonucleotides (Qiagen) using 
LipoGen (Invivogen) following the manufacturer’s instructions. The final concentration of 
siRNA was 100nM. After an incubation of 10hours, the medium was replaced with regular 
medium. MET downregulation in transfected cells was confirmed by Western blot analysis 
48h after. 
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SDS-PAGE and Western Blotting analysis 
 
These methods are used to identify and quantify one or more specific proteins in a complex 
mixture sample. 
 
SDS-PAGE – Sodium Dodecyl Sulfate – Poliacrylamide Gel Electrophoreses 
 
The protein extracts were mixed with sodium dodecyl sulfate (SDS) and denaturated by 
heating at 65ºC for 5 minutes. 
Proteins were fractioned on 7.5% poliacrylamide gel prepared with 29:1 acrylamide/bis-
acrylamide . 
As marker Precision Plus Protein Standards – Dual Color (BioRad) was used. 
Gels were run on BioRad mini-gel apparatus, at 50V for about 1hour and then at 100-150V 
for about 2 hours, until the front of the migration reached the bottom of the gel. 
Electrophoresis buffer used was 1x Tris/Glycine/SDS Buffer (BioRad). 
 
Western Blotting 
 
After electrophoresis proteins were electroblotted onto nitrocellulose membranes (Hybond 
ECL, Amershan Life Science).  
To transfer the proteins we used an electric current to pull them from the gel into the 
membrane, while the initial protein organization is maintained. 
To visualize the uniformity, the overall effectiveness of the transferring and to locate 
molecular weight markers of the proteins, the membrane was stained with Ponceau S dye 
(SIGMA). The membrane was dried and then fragmented according to the protein MW’s 
for the appliance of different primary antibodies.  
The blocking step is crucial to prevent background signals resulting from nonspecifical 
binding to the membranes. Blocking was performed using 5% non-fat dried milk in PBS 
with 0.5% Tween20. The incubation was done at room temperature (RT) for 1hour with 
agitation.  
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The primary antibodies were diluted in 5% non-fat dried milk in PBS 0.5% Tween20 
according to the dilutions shown in the table 1, with the exception of pErk1/2 that was 
diluted in 5% BSA in PBS with 0.5% Tween20. 
 
Table 1. Primary antibodies and respective incubation conditions used for WB analysis. 
Target Antibody WB conditions 
ErbB-2 ErbB-2, clone N3/D10, mouse monoclonal        Ref. CBL755, Chemicon 1:1000, 1h, RT 
MET MET, clone 3D4, mouse monoclonal                 Ref. 18-7366, Zymed 1:1000, 1h, RT 
EGFR EGFR, rabbit polyclonal                                     Ref. #2232, Cell Signaling 1:1000, 1h, RT 
pErk 1/2 p44/42MAPK (Thr202/Tyr204) mouse monoclonal  Ref. 9106, Cell Signaling 1:1000, 1h, RT 
Erk 1/2 p42/p44MAPK rabbit polyclonal                        Ref. 9106, Cell Signaling 1:1000, 1h, RT 
Actin Actin, clone I-19, goat polyclonal                         Ref. sc-1616, Santa Cruz Biotechnology 1:2000, 1h, RT 
 
Incubation with the primary antibody was performed for 1h at RT. After the primary 
antibodies incubation, the membranes were washed in PBS with 0.5% Tween-20 for five 
times, 5 minutes each. 
The appropriate secondary antibodies conjugated with horseradish peroxidase (HRP) 
(Santa Cruz Biotechnology) were then used in a 1:2000 dilution in 5% non-fat dried milk 
in PBS with 0.5% Tween20 to perform a 1 hour incubation with agitation (RT). 
After the secondary antibodies incubation the membranes were washed in PBS with 0.5% 
Tween-20 for 5 times, 5minutes each. 
The membranes were developed with enhanced chemiluminescent (ECL) reagent 
(Amersham Life System Science), according to the manufacturer’s instructions.  The 
peroxide buffer reacts with the HRP to emit light and the luminol/enhacer solution 
intensifies the signal obtained. The signals were detected by exposing the membranes to X-
ray film (Kodak) for a suitable period of time. 
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Immunofluorescence  
 
Immunofluorescence is a technique used for the labeling of proteins with fluorescent dyes. 
This method can be divided in three steps: cell culture, fixation and cell staining.   
In the cell culture, the cells to be stained are attached to a solid support to allow the easy 
handling in the other steps. To achieve this, the cells were grown in coverslips and fixed at 
semi-confluence. 
The step of fixation and permeabilization of the cells ensures free access of the antibody to 
its antigen. The fixation was done using 4% paraformaldehyde in PBS (MERCK). 
Paraformaldehyde is a cross-linking reagent that forms intermolecular bridges, normally 
through free amino groups, creating a network of linked antigens that preserves the cell 
structure. After fixation, cells were permeabilized with 0.2% Triton X-100 in PBS 
(Applichem). This step is needed to the fully access of the antibody to the antigen.  
The cell staining step involves the blocking step, the incubation with the primary antibody 
and the incubation with secondary antibody labeled with a fluorochrome. 
Cells were blocked for 30 minutes with 5% BSA in PBS solution under agitation (the BSA 
has the same function as the non-fat dried milk from the blocking step of the Western 
Blotting). 
Incubations with the primary antibodies were performed for 16 hours at 4ºC with specific 
antibody dilutions in UltraAb Diluent (Lab Vision Corporation) (Table 2). 
 
Table 2. Primary antibodies and respective incubation conditions used for Immunofluorescence analysis. 
Target Antibody Abs conditions 
ErbB-2 ErbB-2, clone N3/D10, mouse monoclonal Ref. CBL755, Chemicon 1:60, 16h, 4ºC 
MET MET, clone 3D4, mouse monoclonal   Ref. 18-7366, Zymed 1:100, 16h, 4ºC 
EGFR EGFR, rabbit polyclonal                       Ref. #2232, Cell Signaling 1:250, 16h, 4ºC 
 
After the primary antibodies incubation the cells were washed in PBS 3 times for 5 
minutes each.  
The cells were then incubated with the appropriated secondary antibodies conjugated with 
fluorescein isothiocyanate (FITC) (DakoCytomation) for 45 minutes at room temperature, 
protected from the light.  
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After the incubation the cells were washed with PBS three times 5 minutes each. 
The coverslips were inverted onto glass slides in mounting medium with DAPI 
(Vectashield) and seen under the microscope. 
The nuclei and specific signals obtained were analysed with a fluorescence microscope 
(Axio Imager Microscope Zeiss), the nuclei stained with DAPI were detected in UV light 
as blue fluorescence, (filter 49, excitation 358nm, emission 463nm), and the signals were 
detected in blue light as green fluorescence (filter 38 HE, excitation 470/40nm, emission 
525/50nm). 
 
 
Proximity Ligation Assay 
 
An important part of the work developed was the establishment and optimization of the 
recent technique Proximity Ligation Assay (PLA). PLA is a new technology developed in 
the Department of Genetics and Pathology at the University of Upsalla, Sweden, by Ulf 
Landegren and colleagues. It is a protein detection method that combines dual recognition 
of target proteins by pairs of affinity probes generating an amplifiable DNA reporter 
molecule which acts as a surrogate marker for the detected protein or interacting proteins.  
The PLA enables the microscopic detection and visualization of individual proteins, 
protein modifications and protein complexes in tissues and cell samples. 
The assay is based on different techniques that are put together to yield high sensitivity. A 
pair of probes with attached oligonucleotides is brought into close proximity by binding 
adjacent proteins and serves as templates for the circularization of so-called connector 
oligonucleotides by enzymatic ligation. The circularized DNA strands remain hybridized 
to the proximity probes, upon addition of phi29 DNA polymerase, and one of the 
oligonucleotides serves as a primer for the rolling circle amplification (RCA), in the 
process unwinding the other oligonucleotide from the DNA circle. The amplification 
reaction generates a randomly coiled, single-stranded product composed up to 1000 
complements of DNA circle, covalently linked to an antibody-antigen complex. This 
product is easily detected through hybridization of complementary fluorescence-labelled 
oligonucleotides as showed in Figure 6 (Soderberg et al., 2006).  
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Figure 6. Schematic presentation of Proximity Ligation Assay method adapted from Duolink PLA User 
Manual. 
 
The samples used were both thyroid and breast cell lines, grown in coverslips, fixed with 
4% paraformaldehyde in PBS (MERCK) and permeabilized with 0.2% Triton X-100 in 
PBS (Applichem).  
The protocol can be divided in seven steps: blocking, primary antibodies incubation, PLA 
probes, hybridization, ligation, amplification and detection. The solutions are from 
“Duolink 100 in situ PLA anti rabbit anti mouse kit” (OLINK). 
All the stock solutions prior being used were diluted 1:5 in high purified water. 
The blocking solution was added to the coverslips and incubated the in a pre-heated humid 
chamber for 30 minutes at 37ºC. 
The primary antibodies were incubated according to the Table 3, following the 
manufacturer’s instructions for the combination of the antibodies. The negative control had 
no primary antibodies, being the coverslip covered only with Antibody Diluent. The 
Blocking Solution was removed from the coverslips and the primary antibody solution was 
added to each sample and incubated in a humid chamber for 16h at 4ºC. 
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Table 3. Primary antibodies for the interactions used for Proximity Ligation Assay. 
Interaction Target Antibodies Abs conditions 
ErbB-2 – ErbB-2  
• ErbB-2 clone N3/D10, mouse monoclonal 
Ref. CBL755, Chemicon 
 
• ErbB-2 rabbit polyclonal Ref. A0485, 
Dako Cytomation 
• 1:40 
 
 
• 1:100 
 
MET – MET 
• MET clone 3D4, mouse monoclonal   Ref. 
18-7366, Zymed 
 
• MET clone CVD13, rabbit polyclonal Ref. 
18-2257, Zymed 
• 1:100 
 
 
• 1:200 
 
ErbB-2 – MET 
• ErbB-2 clone N3/D10, mouse monoclonal 
Ref. CBL755, Chemicon 
 
• MET clone CVD13, rabbit polyclonal Ref. 
18-2257, Zymed 
• 1:40 
 
 
• 1:200 
 
MET - EGFR 
• MET clone 3D4, mouse monoclonal   Ref. 
18-7366, Zymed 
 
• EGFR, rabbit polyclonal                       
Ref. #2232, Cell Signaling 
• 1:100 
 
 
• 1:250 
 
ErbB-2 – EGFR 
• ErbB-2 clone N3/D10, mouse monoclonal 
Ref. CBL755, Chemicon 
 
• EGFR, rabbit polyclonal                       
Ref. #2232, Cell Signaling 
• 1:40 
 
 
• 1:250 
 
 
After the incubation the coverslips were washed with Tris-Buffered Saline – Tween 20 
(TPS-T) for 2 times, 5 minutes each, under gentle agitation 
Then two PLA probes were diluted 1:5 in Antibody Diluent, added to the coverslips and 
incubated in a pre-heated humid chamber for a maximum of 2h at 37ºC. 
The coverslips were washed in TBS-T for 2 times, 5 minutes each, and the Hybridization 
solution was added to each sample and incubated in pre-heated humidity chamber for 15 
min at 37°C. 
The coverslips were washed with TBS-T for 1 minute under gentle agitation, the Duolink 
Ligase was diluted 1:40 to the Ligation solution and the coverslips were incubated in a pre-
heated humid chamber for 15 minutes at 37ºC. After the incubation the coverslips were 
washed with TBS-T for 2 times, 5 minutes each. 
The Duolink Polymerase was added to the Amplification solution at 1:80 dilution and the 
samples were incubated in a pre-heated humid chamber for 90 minutes at 37ºC. The 
coverslips were washed with TBS-T for 2 times 5 minutes each. 
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 The Duolink Detection was added to each sample and incubated in a pre-heated humid 
chamber for 60 minutes at 37ºC protected from the light. 
The coverslips were washed in a series of washes, 2 minutes each, in SSC 2x, SSC 1x, 
SSC 0.2x, SSC 0.02x, and then 20 seconds in 70% ethanol. The coverslips were protected 
from light during the procedure. 
For the preparation of the imaging slides were covered with 3µl of mounting medium 
(Vectashield) and the dried coverslip were place on it.  
The  nuclei and signals obtained were analysed with a fluorescence microscope (Axio 
Imager Microscope Zeiss), the nuclei were stained with Hoechst 33342 and detected in UV 
light as blue fluorescence, (filter 49, excitation 346nm, emission460 nm), and the signals 
were detected in green light as red fluorescence (filter 43 HE, excitation 550/25nm, 
emission 605/70nm). 
The images captured on the fluorescent microscope were analysed with “BlobFinder” 
software, developed in the Centre for Image Analysis at Uppsala University, which counts 
the hybridization signals in each cell.  
 
 
Immunohistochemistry 
 
The immunohistochemistry technique enables the localization of proteins in cells of a 
tissue section exploiting the well-known principle of antibody-antigen specific binding.  
The immunohistochemistry performed was based on a streptavidin-biotin staining method 
where a biotinylated secondary antibody links the primary antibodies to a streptavidin-
peroxidase conjugate. A single primary antibody was therefore, associated with multiple 
peroxidase molecules that considerably increased its sensitivity. Peroxidase activity in the 
presence of the electron donor resulted in the formation of an enzyme-substrate complex, 
which oxidized the electron donor 3,3’-diaminobenzidinetrahydrochloride (DAB) 
producing a brown end product highly insoluble in organic solvents. 
 
Immunohistochemical procedure were performed in the TMAs using the primary antibody 
towards MET, clone CVD13 rabbit polyclonal (Zymed). The negative control used was a 
thyroid preparation known positive for MET protein. 
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The TMAs and the negative control were deparaffinised in Clear-Rite (Richard-Allan 
Scientific,  Thermo Scientific) for 20 minutes and rehydrated in graded alcohols (100% 
and 70% v/v), and ddH2O 5 minutes each. The antigen retrieval used was the Target 
Retrieval Solution pH 9.0 (DakoCytomation) for 20 minutes at 98ºC in a water bath. 
After being at RT for at least 20 minutes, the preparations were then washed in PBS 0.02% 
Tween-20 for 3 times, 5 minutes each, and incubated with 200µL of 3% v/v hydrogen 
peroxide in methanol for 10 minutes at room temperature, to inhibit endogenous 
peroxidase. In order to block unspecific binding, an incubation of 10 minutes at room 
temperature was performed using 100µL Ultra V Block solution (Lab Vision Corporation). 
Sections were then incubated, overnight at 4ºC, with the primary antibody previously 
diluted 1:400 in UltraAb Diluent (Lab Vision Corporation), and the negative control was 
incubated only with UltraAb Diluent. 
The next day the samples were washed 3 times, 5 minutes each, in PBS 0.02% Tween-20 
and overlaid with 100µL of secondary antibody (Biotinylated Goat Anti-Polyvalent, Lab 
Vision Corporation) for 10 minutes. 
Localization was performed via the application of 100µL of Streptavidin Peroxidase (Lab 
Vision Corporation) for 10 minutes at room temperature. The sections were then stained 
with 100µL of liquid (DAB) (DakoCytomation Liquid DAB + Substrate Chromogen 
System, DAKO Corporation) for 5 minutes and counterstained with Meyer’s 
Haematoxylin (J. T. Baker, Deventer, Holland) during 2 minutes. 
Using graded alcohols, 95% and 100%, sections were dehydrated for 5 minutes in each and 
placed in Clear-Rite to allow further coverslips mounting with Entellan (Richard-Allan 
Scientific). 
The stained TMAs were further visualised, and analysed in a multi-head microscope (Zeiss 
Axioskop2) and a proper classification was performed by two observers, being one a 
specialized Pathologist. The MET expression was assessed in terms of intensity and 
extension of the staining on the cellular location according to the table 4. Only a clear 
membranar staining was considered as specific. Cases with MET intensity of staining 0 or 
1+ were considered negative expression, and cases with 2+ and 3+ were considered 
positive expression.  
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Table 4. Immunohistochemical classification. 
Score Intensity of staining 
0 Absence of staining 
1+ Weak staining 
2+ Intermediate staining 
3+ Strong staining 
 
 
Statistical analysis  
 
The analysis of the immunohistochemistry results was completed using SPSS Statistics 
17.0 for Windows software. Correlations between clinicopathological factors and MET 
were performed using Pearson chi-square test. The survival of the patients was performed 
by obtaining the Kaplan Meier survival curve, with significance evaluated using Log-rank 
test.  
The prognostic significance was assessed using Univariate Cox-proportional hazards 
model, and the determination of independent prognostic factors on the survival was 
performed by Multivariate analysis applying Cox regression model on the variables with 
statistical significance in univariate analysis. The cases with a follow-up minor than 2 
years were not taken in account. P value was considered significant when P<0.05.  
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Results  
 
 
Expression of MET, ErbB-2 and EGFR in carcinoma-derived cell lines  
 
MET, ErbB-2 and EGFR are coexpressed in thyroid and breast carcinomas cell lines.
  
A preliminary classification and quantification of the expression of the proteins MET, 
ErbB2 and EGFR in the different cell lines was made by Western blot and 
Immunofluorescence.  
From all the cell lines, four that expressed all the target RTKs were selected, TPC-1 and 
8505C from pappilary and undiferentiated thyroid carcinomas, respectively, and MDA-
MB-231 and SkBr3 from basal and ErbB-2 OE breast carcinomas, respectively. The 
selected cell lines allowed a good coverage of different subtypes of carcinomas and the 
respective caracterization in the subsequent studies.  
 
 
 
 
               Figure 7. MET (145kDa), EGFR (170kDa) and ErbB-2 (185kDa) are present in both thyroid 
(TPC-1 and 8505C) and breast (MDA-MB-231 and SkBr3) cell lines. Whole cell lysates from TPC-1, 
8505C, MDA-MB-231 and SkBr3 were separated by SDS-PAGE and analysed for MET, EGFR and ErbB-2 
expression by Western Blot. Actin was used as loading control. 
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As shown by Western Blot (Figure 7) and Immunofluorescence (Figure 8) MET, EGFR 
and ErbB-2 are expressed, at different levels, in all the selected cell  lines. 
By immunofluorescence the target RTKs expression are observed mainly in the cytoplasm 
and in the membrane. The Western Blot and Immunofluorescence images from the remain 
cell lines are shown in the Annexe 2. 
 
 
Figure 8. MET, EGFR and ErbB-2 are present in both thyroid (TPC-1 and 8505C) and breast (MDA-MB-
231 and SkBr3) cell lines (400x). The MET, EGFR and ErbB-2 are stained green (FITC) and the nuclei are 
stained blue (DAPI). 
  
 
 
MET, EGFR and ErbB-2 interactions. 
 
The presence of RTKs interaction complexes were assessed by Co-Immunoprecipitation 
and by Proximity Ligation Assay.  
MET EGFR 
8505C 
TPC-1 
MDA-MB-231 
SkBr3 
ErbB-2 
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ErbB-2 co-immunoprecipitated with MET but EGFR did not, in all the four cell lines in 
study. These results suggest that only ErbB-2 and MET are found in a protein complex and 
that EGFR does not form a physical complex with MET (Figure 9). The WB of MET is 
used as a control to demonstrate the endogenous levels of MET expression. 
 
     
 
 
  Figure 9. MET interacts with ErbB-2, but not with EGFR in TPC-1 (A), 8505C (B), MDA-MB-231(C) and 
SkBr3 (D).  Immunoprecipitation with IgG mouse was used as a negative control in each experiment. 
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In the Proximity Ligation Assay the hybridization signals found in the cells represent the 
interaction between the proteins in study. A fluorescence microscope image overlapped 
with a schematic representation of the software analysis can be seen on figure 10.  
 
  
Figure 10. The MET- ErbB-2 interaction in the 8505C cell line by PLA technique is shown (as an example 
of PLA results). A – Fluorescence microscope image, the nuclei are stained in blue and the hybridization 
signals in red (400x). B (inset) – Overlay between images from the fluorescent microscope and the software 
analysis scheme. 
 
For each cell line, the interactions between MET and ErbB-2 were characterized. In each 
interaction assay, negative control experiments were performed which resulted in 
negligible amounts of signals (Figure 11).  
In all the cell lines the interaction found in higher number was MET–MET, with the 
exception of SkBr3 which due to the overexpression of ErbB-2 the ErbB-2–ErbB-2 was 
the principal interaction. The MET-ErbB-2 interaction was found in all the cell lines in 
study, confirming the previous Co-IP results. 
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Figure 11. MET and ErbB-2 interactions in TPC-1, 8505C, MDA-MB-231 and SkBr3 cell lines, analysed by 
Proximity Ligation Assay. The histograms indicate the number of MET and ErbB-2 interactions (residual 
control values are not always visible). CN, negative control. 
 
 
Increased level of ErbB-2 expression upon downregulation of MET. 
 
The MET expression was downregulated by treatment of TPC-1, MDA-MB-231 and 
SkBr3 cells with MET siRNA. Under knockdown conditions western blot was performed 
to assess variations in the expression of MET, ErbB-2, phospho and total Erk and PLA was 
performed to assess the MET–MET, MET–ErbB-2 and ErbB-2–ErbB-2 interactions.  
As shown in Figure 12, the downregulation of MET was concomitant with an increase of 
ErbB-2 expression in TPC-1 (1.3-fold increase) and MDA-MB-231 (1.5-fold increase) 
cells. The SkBr3 cells didn’t show an evident increase of ErbB-2, however, in this cell line 
the number of ErbB-2 homodimers increase in comparison to the non-downregulated cells 
(Figure 13). 
No differences were seen in phosphorylated or total ERK expression either in the control 
or MET siRNA conditions. 
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Number of 
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Figure 12. Western blot analysis of MET, ErbB-2, Erk1/2 activation in TPC-1 (A), MDA-MB-231 (B), and 
SkBr3 (C) cells after MET downregulation. Actin was used as control. 1. Control cells (no treatment); 2. 
Control cells treated only with Lipogen; 3. Control cells treated with scramble RNA oligonucleotides; 4. 
Cells treated with MET siRNA. 
 
 
Figure 13. MET and ErbB-2 interactions analysed by Proximity Ligation Assay in TPC-1, MDA-MB-231 
and SkBr3 cell lines after MET downregulation. The histograms indicate the number of MET and ErbB-2 
interactions (negative control residual values not always visible). The dark shade histograms demonstrate the 
MET and ErbB-2 interactions in the cell lines without MET downregulation. CN, negative control. 
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In all the cell lines in study the MET downregulation is quite evident by PLA analysis 
(Figure 13). Also a slightly increase in the number of MET-ErbB-2 and ErbB-2-ErbB-2 
dimers is seen in TPC-1 and SkBr3. 
 
 
MET in Tissue Samples 
 
Immunostaining for MET 
  
The breast tumours used in this part of the study had been previously classified in subtypes 
and by grade. In the series used the most established markers for breast carcinogenesis 
(ER, PR, ErbB-2, P53, P63 and P-cadherin) had already been tested. 
MET staining was localised both in cytoplasm and membrane (Figure 14), but only the 
membrane staining was taken in account, being the cytoplasm staining considered 
“background” of the primary antibody. The MET staining exhibited considerable 
variations between the different types of tumours, but was substantially stronger than in the 
surrounding normal tissues where almost no staining was observed.   
 
  
Figure 14. Immunohistochemical staining of MET in two different breast cancer cases (400x). MET 
membranar expression considered as positive staining is indicated by blue arrows. 
 
 
The Pearson chi-square analysis results are summarized in Table 5. MET membranar 
staining was correlated with the molecular subtypes classification (P=0.002), ErbB-2 
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expression (P=0.038), and absence of ER (P=0.004). Also a significative correlation 
between MET and Grade (P=0.023) was observed. 
MET expression was not significantly correlated to other establish prognostic factors such 
as age, lymph node metastasis, PR, P-cadherin, EGFR, p53 and p63. 
 
Table 5. Statistical comparison between the presence/absence of MET and the clinicopathologic 
characteristics of breast cancer.  
MET N(%) 
Variables N 
+ - 
P valuea
Luminal 124 43 (34.68%) 81 (65.32%) 
ErbB-2 OE 20 15 (75.00%) 5 (25.00%) Molecular subtypes 
TN 51 25 (49.02%) 26 (50.98%) 
0.002 
+ 32 19 (59.38%) 13 (40.62%) 
ErbB-2 
- 167 66 (39.52%) 101 (60.48%) 
0.038 
+ 121 42 (34.71%) 79 (65.29%) 
ER 
- 78 43 (55.13%) 35 (44.87%) 
0.004 
+ 80 31 (38.75%) 49 (61.25%) 
PR 
- 119 54 (45.38%) 65 (54.62%) 
0.354 
+ 13 8 (61.54%) 5 (38.46%) 
EGFR 
- 186 77 (41.40%) 109 (58.60%) 
0.156 
+ 3 1 (33.33%) 2 (66.67%) 
p63 
- 196 84 (42.86%) 112 (57.14%) 
0.741 
+ 43 20 (46.51%) 23 (53.49%) 
p53 
- 156 65 (41.67%) 91 (58.33%) 
0.570 
+ 53 27 (50.94%) 26 (49.06%) 
P-cadherin 
- 146 58 (39.72%) 88 (60.27%) 
0.157 
+ 87 42 (48.28%) 45 (51.72%) 
Lymph node metastasis 
- 74 28 (37.84%) 46 (62.16%) 
0.183 
I 90 32 (35.56%) 58 (64.44%) 
II 79 34 (43.04%) 45 (56.96%) Grade 
III 24 16 (66.66%) 8 (33.34%) 
0.023 
Age 199 85 (42.71%) 114 (57.29%) 0.611 
a. P value (Pearson chi-square test) was considered significant when P<0.05. Statistically significant 
observations are in blue-boldface. 
 
To evaluate the prognostic significance of MET in the invasive breast cancer disease a 
Kaplan-Meier survival analysis was performed (Figure 15). The Kaplan-Meier curve 
  Results 
  35
   
demonstrated that MET expression was related to a worse prognosis having these patients 
a short disease-related survival in the 13-year follow-up period (P=0.004). 
 
Figure 15. Kaplan-Meier analysis of disease-related survival demonstrates that the presence of MET tend to 
increase a worse prognosis and an earlier death. Statistical significance was assessed using the Log-rank test.  
 
In Luminal, ErbB-2 OE and triple negative subtypes the Kaplan Meier test was also 
performed to observe the role of MET in the disease-related survival of each subtype of 
tumours (Figure 16).  
In the patients with luminal subtype tumours the Kaplan-Meier curve is identical to that 
obtained for the overall subtypes being MET expression  correlated with a shorter  disease-
related survival (P=0.015). The same tendency found in the patients with Luminal subtype 
was observed those with triple negative tumours, although without reaching significance. 
At variance the patients with ErbB-2 OE tumours expressing MET presented a better 
outcome, showing a tendency to higher disease-related survival.  
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Figure 16. Kaplan-Meier analysis of disease-related survival in Luminal (A), ErbB-2 OE (B) and Triple 
negative (C) subtypes of tumours. Statistical significance was assessed using the Log-rank test. 
 
 
 
 
Clinicopathological  factors and survival. 
  
To determine the predictive influence on survival of breast cancer prognostic variables a 
univariate analysis of 11 clinicopathological factors was performed. The prognosis was 
significantly related to 8 of the 11 variables analysed, MET, ErbB-2, ER, PR, p63, P-
cadherin, grade and age (Table 6), where ER and PR had a correlation with better 
prognosis (Relative risk <1) and the remain factors were correlated with a worse prognosis 
(Relative risk >1). 
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Table 6. Univariate analysis of the clinicopathologic factors for the 13-year disease-related survival. 
Univariate Analysis 
Variables 
Relative Risk P valuea 95% C.I. 
MET 2.554 0.006 1.303 - 4.996 
ErbB-2 2.320 0.025 1.111 - 4.842 
ER 0.493 0.021 0.271 - 0.898 
PR 0.509 0.047 0.261 - 0.991 
EGFR 1.643 0.408 0.507 - 5.321 
p63 4.482 0.040 1.075 - 18.693 
p53 1.864 0.057 0.981 - 3.541 
P-cadherin 2.006 0.030 1.071 - 3.757 
Subtypes  1.371 0.051 0.998 - 1.882 
Grade 1.883 0.002 1.273 - 2.785 
Age 1.026 0.033 1.002 - 1.050 
a. P value was considered significant when P<0.05 by Cox-proportional hazards model. C.I. 
confidence interval. Statistically significant observations are in blue-boldface. 
 
 
Multivariate analysis using the Cox proportional hazards model involving the 8 significant 
factors determined by Univariate analysis was performed (Table 7).   
MET was the only clinicopathological factor that remains significant (P=0.041) in this 
analysis, which indicates that MET is an independent predictor of poor prognosis, 
confirming the previous data. 
 
Table 7. Multivariate analysis of the 13-year disease-related survival using only the statistically significant 
clinicopathologic factors from the univariate analysis.  
Multivariate Analysis 
Variables 
Relative Risk P valuea 95.0% C.I. 
MET 2.115 0.041 1.030 - 4.345 
ErbB-2 1.955 0.135 0.812 - 4.704 
ER 1.067 0.889 0.430 - 2.651 
PR 0.683 0.454 0.251 - 1.856 
p63 3.741 0.226 0.442 - 31.689 
P_cadherin 1.382 0.440 0.608 - 3.139 
Grade 1.366 0.225 0.826 - 2.259 
Age 1.027 0.074 0.997 - 1.058 
a. P value was considered significant when P<0.05 by Cox-proportional hazards model. 
C.I., confidence interval. Statistically significant observations are in blue-boldface. 
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Discussion 
 
 
Historically, RTKs define the prototypical class of oncogenes involved in most forms of 
human malignancies (Robinson et al., 2000).  
This study is focused on RTKs expression and interactions of ErbB and HGFR families 
that have overlapping functions in initiation and progression of cancer. EGFR and ErbB-2 
are implicated in promoting proliferation and survival and MET has an important role in 
cell motility and epithelial/mesenchymal transition, although its function is a matter of 
continuous debate (Agarwal et al., 2009). 
This work was primarily performed in five thyroid carcinoma-derived cell lines (TPC-1, 
8505C, C643, K1 and XTC-1). The MET, EGFR and ErbB-2 expression was detected, in 
different levels, by Western Blot and Immunofluorescence and their interactions were 
analysed by Proximity Ligation Assay and Co-Immunoprecipitation. Subsequently the 
MET–ErbB-2 interaction was the only dimer confirmed between ErbB and HGFR families.  
In 2007 Guo et al., to understand the sensitivity of some tumours to target kinase 
inhibitors, described the physical interaction MET-EGFR and observed that Gefitinib, a 
selective inhibitor towards EGFR, besides inhibiting EGFR also inhibited phosphorylation 
of ErbB-2, ErbB-3 and MET in NSCLC cell lines. They also predicted that MET could 
interact with others RTKs like EGFR, ErbB-2 and ErbB-3 in MKN45, a gastric carcinoma-
derived cell line. 
In 2008 Shattuck et al., described that MET and ErbB-2 are co-expressed in ErbB-2 OE 
breast cancer cells and tumours. When they treated the cell lines with Trastuzumab, a 
humanized monoclonal antibody directed against ErbB-2, they observed a significant 
increase in MET expression, accompanied by an increase in MET transcript levels, which 
they observed that contributed to Trastuzumab resistance through the sustained activation 
of downstream signalling activation.  
In 2009 Agarwal et al., described that MET physical interacts with both EGFR and ErbB-2 
in NSCLC cell lines with overexpression/ overactivation of MET. In this study they 
suggested a simultaneous inhibition of multiple RTKs to effectively abrogate tumour cell 
growth. 
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Since our results were consistent with the recent studies from Guo et al., 2007; Shattuck et 
al., 2008 and Agarwal et al., 2009, with the exception that we did not observed MET-
EGFR interaction, in collaboration with the Breast Cancer Group, aiming a better 
understanding of the clinical and prognostic significance of the MET–ErbB-2 interaction, 
we decided to extend our work to breast cancer.  
The breast cancer is a very well studied cancer model. It is a very aggressive disease, 
where ErbB-2 is a well studied and important prognosis factor with already a targeted 
therapy approved, Trastuzumab. Due to these facts we have decided that breast cancer 
should be our model to better understand the impact of MET expression and interactions 
with ErbB-2. 
The selected breast carcinoma-derived cell lines used were SkBr3, from ErbB-2 OE 
tumour subtype, and MDA-MB-231, from basal tumour subtype, in which, like in thyroid, 
we found MET, EGFR and ErbB-2 expression and MET–ErbB-2 interactions.  
The MET downregulation by siRNA was performed to observe if any alterations occur in 
either ErbB-2 and/or pERK1/2 expression. Indeed, in both thyroid and breast carcinoma-
derived cell lines, it was observed an increase in ErbB-2 expression by Western blot, with 
the exception of SkBr3 cell line possibly due to the fact that this cell line has ErbB-2 
overexpression and subsequently the variation of the protein expression was not detectable 
by this technique. However, the increase of ErbB-2 expression upon downregulation of 
MET was detected by PLA where the ErbB-2 homodimers were found in higher number 
than in cells without treatment. The MAPK pathway was found not to be altered with the 
downregulation of MET, since no effect was observed in either pErk1/2 or in Erk 1/2 
expression by Western blot. In Shattuck et al., 2008, they observed that when ErbB-2 was 
inhibited with Trastuzumab, a significant increase in MET expression occurred. These, 
although mirroring our results, are consistent with our observations of the increase 
expression of ErbB-2 when MET was downregulated. Taking together, they suggest that a 
kind of cross-talk at the expression level seems to exist between both receptors that deserve 
further exploration. They also observed that with MET downregulation both MAPK and 
PI3K/AKT pathways diminished downstream signalling. As previously discussed we 
couldn’t see these results in our experiments towards MAPK pathway, and we did not 
study PI3K/AKT pathway.  
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The PLA results from the MET downregulation showed that, while the MET–MET 
interactions decreased due to its downregulation, the number of interactions MET–ErbB-2 
and ErbB-2–ErbB-2 slightly increased in TPC-1 and SkBr3 cell lines. A possible 
explanation for these results is a competitive RTKs dimer formation model. It is known 
that both ErbB-2 and MET dimerize with others RTKs like EGFR and ErbB-3. If the 
receptors compete for the formation of dimers it is possible that when a RTK is 
downregulated, like MET, the others RTKs, like ErbB-2, which the expression was 
increased with the downregulation of MET, will compete with the existing MET and form 
heterodimers instead of homodimers, since ErbB-2 is available in higher number. 
Further investigation is necessary to understand the dimers formation, the underlying 
mechanisms of these interactions, if they are functionally active, and their role in cell 
stimulation. 
After the in vitro analysis, an in vivo study was performed in a series of invasive breast 
carcinomas. 
From the analysis of the immunohistochemistry results in breast tumours we have observed 
that MET is not randomly expressed within the tumours, it is significantly associated with 
some clinicopathological factors like grade, molecular subtype, ER negative and ErbB-2 
positive expression. MET expression is increased in high grade tumours since we observed 
MET expression in 66.7% in grade III tumours in opposition to 35.5% in grade I.  Similar 
results were observed in the relation between MET and molecular subtypes. The 
expression of MET is inversely related to the expression of ER, which is associated to the 
Luminal subtype, where only 35% of the cases expressed MET. The Luminal subtype is 
known to express ER and to be the less aggressive breast cancer subtype. According to the 
association between MET expression and higher aggressiveness of the tumours, we found 
co-expression of MET in 75% of the ErbB-2 OE cases, being the association between 
MET and ErbB-2 the exact opposite of MET and ER. 
In the literature MET was already related to an adverse outcome in breast cancer patients 
(Kang et al., 2003; Ocal et al., 2003; Lengyel et al., 2005 and Lindemann et al., 2006), but 
it was never related to the established clinicopathological factors.  
Our results are in agreement with literature and in addition, we found MET to be 
significantly associated to other prognosis factors and also with survival, where the 
Kaplan-Meier analysis of disease-related survival demonstrates that the patients with 
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tumours expressing MET have a significative lower survival rate. In patients, with Luminal 
subtype tumours, MET expression is related to a significative poorer survival, which is in 
accordance to the previous results. 
However, we have seen a duality of MET role on survival. Unexpectedly, in patients with 
ErbB-2 OE subtype the survival was higher when MET was expressed, which might 
indicate that when the tumours have a highly aggressive behaviour the presence of MET 
can be predictive for a better patients outcome. Further research is necessary to understand 
better the effect of MET in the different subtypes of tumours. 
In the final part of our study, we considered important to know which prognostic factors 
were related to the survival of the patients. By univariate analysis we observed that MET, 
ErbB-2, ER, PR, p63, P-cadherin, grade and age were factors with significative influence 
on the survival of the patients. Both ER and PR have a significantly correlation with a 
better prognosis of the patients. Indeed, these results are in accordance to the breast cancer 
subtypes classification, where these receptors expression are correlated with Luminal 
subtype tumours, which patients have a better clinical outcome. MET, ErbB-2, p63, P-
cadherin, grade and age have a significative correlation with a poorer prognosis of the 
patients, which is according to the previous results and literature. MET, ErbB-2 expression 
and grade are related to a patients poorer clinical outcome, p63 is a factor associated with 
metaplastic carcinomas (Koker and Kleer, 2004) and P-cadherin expression is associated 
with tumour aggressiveness (Paredes et al., 2005). 
By multivariate analysis MET was the only clinicopathological factor that remained 
significant (P=0.041). This result indicates that MET, independently of the other prognosis 
factors, can identify a subset of patients with an adverse outcome of the disease, 
confirming the previous data and literature. 
All these results indicate that the presence of MET is related to a worse prognosis of the 
patients, and that the association and interactions between MET and ErbB-2 are important 
to consider. This study leads to the hypothesis that targeting MET alone or with ErbB-2 
may be very important in the treatment of breast cancer.  
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Conclusions  
 
 
In this study we have observed MET, ErbB-2 and EGFR expression in both thyroid and 
breast carcinomas-derived cell lines, and demonstrated by Co-IP and PLA techniques 
MET–ErbB-2 physical interaction in all the cell lines. We have also observed an increase 
in ErbB-2 expression upon MET downregulation, suggesting a transcriptional cross-talk 
between expression levels of the two RTKs. Further studies on the role of MET–ErbB-2 
interaction on cell biology are essential. 
In breast tumours we have demonstrated that MET expression is an independent prognostic 
factor related to a general poorer survival of the patients, which is clearly associated with 
other important prognosis factors such as ErbB-2, ER, grade and subtypes. Unexpectedly 
MET expression seems to exert a protective behaviour on survival of patients with ErbB-2 
OE tumours subtype, if confirmed in a larger series this can be an important matter for 
further investigation.  
Taken together, our data has showed an interesting cross-communication between MET 
and ErbB-2 RTKs in both thyroid and breast carcinomas, which might be helpful for the 
design of new targeted therapies.    
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Annexe I  
 
 
Solutions used in Material and Methods 
 
Wash Buffers 
 
- Phosphate Buffered Saline – PBS 10x 
 
To prepare 1L add 80g of Sodium chloride (NaCl), 2g of Potassium chloride (KCl), 14.4g 
of Sodium phosphate dibasic (Na2HPO4) and 2.4g of Potassium phosphate monobasic 
(KH2PO4) to 1L of ddH20. Adjust pH to 7.4 and store at room temperature. 
 
- PBS1x 0.02% Tween 20 
 
To prepare 1L add 100mL of 10x PBS to 900mL of ddH20, 20μL of Tween 20 and mix. 
Store at room temperature. 
 
- Salt Sodium Citrate – SSC 20x 
 
Dissolve 17.5g NaCl and 8.8g Sodium citrate (Na3C3H5O(COO)3) into 1L ddH20. Adjust 
pH to 7.0. Filter the solution through a 0.22 μm filter and store at +4°C. 
 
- Tris Buffered Saline – TBS Tween 20 
 
Dissolve 8.8g NaCl, 1.2g Tris base and 0.5 ml Tween 20 into 1L ddH20. Adjust pH to 7.4. 
Filter the solution through a 0.22 μm filter and store at +4°C. 
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Protein extraction 
 
- Ripa lysis buffer  
 
Add 50mM Tris-HCl, 1%NP-40, 150mM NaCl and 2mM EDTA into ddH20. Adjust pH to 
7.5 and store at 4ºC. Before use add 1% fosfatases’ inhibitor and 7% proteases’ inhibitor in 
PBS. 
 
 
Co-Immunoprecipitation  
 
- Catenin Lysis Buffer 
 
Add 1% Triton X-100, 1% NP40 in PBS1x. 
 
- Buffer C 
 
For 50ml final volume add 5ml of Catenin Lysis Buffer, 250mg Sodium diphosphate 
(Na4P2O7), 0.5ml Sodium fluoride (NaF) in the total volume of PBS1x. 
 
 
Immunohistochemistry  
 
· Peroxidase Inhibition 
 
- 3% v/v Hydrogen Peroxide 
To prepare approximately 2 mL, add 200μL of 30% Hydrogen peroxide (H2O2) to 2mL of 
methanol (CH3OH). Notice that this solution has to be prepared a few moments before 
being used. 
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Annexe II   
 
Characterization of MET, EGFR and ErbB-2 expression, obtained by Immunofluorescence 
and Western Blot, in C643, K1, XTC-1 and MCF-7 cells lines. 
 
 
Immunofluorescence 
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Western Blot 
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